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BACKGROUND: Additional prognostic markers are needed for better treatment stratification of stage II colon
cancer (CC). We investigated the prognostic value of tumor-infiltrating lymphocytes (TILs) in a true population-
based cohort of patients with stage II CC.MATERIAL AND METHODS: A total of 573 patients were included. Tumor
blocks representing the deepest invasive part of the primary tumor were used for analysis. CD3+ and CD8+ TILs
at the invasive front were evaluated by immunohistochemistry on whole tumor sections. The invasive area was
manually outlined, and Visiopharm Integrator System software was used for quantification. Data were
dichotomized for comparison with clinical data. The prognostic value was investigated in Cox proportional-hazard
models for recurrence-free survival (RFS) and overall survival (OS). RESULTS: Low CD3+ or CD8+ TILs were
significantly associated with poor RFS and OS (P = .0021 and P ≤ .0009, respectively, log-rank test). In multiple
Cox regression analysis, low CD3+ and CD8+ TILs were associated with reduced RFS with hazard ratio
(HR) = 1.386 (95% CI 1.039-1.850), P = .026, and HR = 1.394 (95% CI 1.029-1.890), P = .032, respectively,
independent of age, T-stage, localization, perforation, and microsatellite instability (MSI). In the subgroups of
patients with low CD3+ or CD8+ TILs, there was no difference in survival between patients with MSI and
microsatellite-stable tumors, (P = .821 and P = .907, respectively). CONCLUSION: Low CD3+ and CD8+ TILs in
the invasive area are both related to inferior prognosis of stage II CC, and we recommend either of these
parameters to be considered as additional high-risk factor.
Translational Oncology (2018) 11, 979–987play any role in the study design, data collection, analysis or interpretation of the data,
decision to publish, or preparation of the manuscript.
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Patients with stage II colon cancer (CC) generally have a good
prognosis, with a 5-year overall survival (OS) of 70%-80% after
surgery alone [1], and the efficiency of adjuvant chemotherapy is
often debated. Current international guidelines (ASCO and ESMO)
do not recommend routine adjuvant treatment. Such therapy should
be limited to patients at high risk of recurrence [2,3]. However, the
current risk factors are insufficient for ideal selection of adjuvant
therapy [4], and there is a need for additional prognostic markers for
better clinicoprognostic stratification of stage II CC. In this context,
tumor-infiltrating lymphocytes (TILs) may represent a promising
marker. So far, the TNM classification is considered the most
valuable system for categorization, and TILs have been proposed as a
component for classification of primary colorectal carcinomas [5].
TILs have been investigated in various settings in colorectal cancer
(CRC), but most studies include heterogeneous study populations
with both colon and rectal cancer. Preoperative treatment of rectal
cancer with radiotherapy is known to decrease the number of TILs [6]
and thus might complicate the interpretation of the prognostic value.
Few studies have exclusively investigated CC [7–9], and they include
different stages of the disease. Hence, conclusions regarding stage II
CC are difficult to extract.
To facilitate TILs as a clinical biomarker in CRC, an Immunoscore
has been proposed, and a multinational investigation of the practical
implementation and clinical impact is in progress [10]. The
Immunoscore is based on estimates of two different populations of
T-lymphocytes counted in two different areas of the tumor and
defined as the central and the invasive front. TILs mainly consist of T-
cells (CD3+), including a subgroup of cytotoxic T-cells (CD8+),
which have the ability to kill target cells. For prognostic purposes,
CD3+ and CD8+ TILs have appeared to be informative. Galon et al.
investigated CD3+ cells in the central part of the tumor and at the
invasive margin with an improved prognostic value obtained by the
latter [11].
Several studies of CRC have demonstrated high occurrence of CD3
+ [12,13] and CD8+ TILs [11,14,15] to be associated with improved
survival, but separate data for stage II CC are limited. Only one study
by Lee et al. [16] has exclusively investigated TILs in stage II CC.
They demonstrated a prognostic value of CD3+ TILs, but their
cohort was small (N = 87), and their results were not of independent
significance in a multiple Cox analysis. Furthermore, they did not
investigate CD8+ TILs. Thus, the prognostic value of CD3+ and
CD8+ TILs in stage II CC remains largely unknown.
With this motivation, the objective of the present study was to
evaluate the prognostic impact of CD3+ and CD8+ TILs in the
invasive tumor front in a nationwide population-based cohort of stage
II CC.
Material and Methods
This study is reported in accordance with the REMARK criteria [17].
Patient Population
All patients treated surgically for stage II CC in 2002 in Denmark
(N = 746) were identified by a search in the nationwide registry
administered by the Danish Colorectal Cancer Group (DCCG). The
database contains prospectively collected surgical and pathological
data. All pathology departments in Denmark agreed to participate in
the study, and thus the cohort represents the entire Danish
population of stage II CC in 2002. The following exclusion criteriaapplied: tumor blocks missing in archives (N = 11), insufficient tissue
for analysis (N = 1), stage II not recognized in new sections cut (N =
21), suspicion of stage IV (N = 4), patients treated with adjuvant
chemotherapy (N = 26)/radiotherapy (N = 1), and death within
90 days of surgery (N = 75). Patients with loco-advanced disease
(N = 8) were excluded, and the same applied to patients diagnosed
with another malignancy before primary CC (N = 26). The final
study population comprised 573 patients.
Tumors located from the cecum to the transversum were defined as
right-sided, and those located from the left colonic flexure to the
sigmoideum were defined as left-sided.
Patients with histologically verified recurrence were identified
through PatoBanken, i.e., the national registry containing all
pathology reports in Denmark. Patients diagnosed with other
histologically verified malignancies were also identified using this
registry and subsequently censored from the recurrence-free survival
(RFS) analysis on the date of their new cancer diagnosis. Information
on treatment with adjuvant chemotherapy, nonhistologically verified
recurrence, or diagnosis of other malignancies was obtained from the
National Patient Registry containing information on all Danish
citizens' contacts to the healthcare system linked by the unique
personal identification number.
The follow-up period was 7 years and began at the date of surgery.
This interval was selected since most patients experienced recurrence
within 5 years from being diagnosed with their primary disease and 7
years thus encompasses the majority of recurrences. Data on T-
category, malignancy grade, localization, number of lymph nodes,
and neural and vascular invasion were obtained from the pathology
reports. Whenever inconclusive on T-stage or differentiation, the
decision was made by microscopy of new sections. Information on
tumor perforation, ileus, and type of surgery was obtained partly from
the pathology reports and partly from the DCCG Registry based on
the surgeon's report.
The study was approved by The Regional Committees on Health
Research Ethics for Southern Denmark (S-20140119) and the
Danish Data Protection Agency (14/26345). All patients were
screened in the Danish Registry of Tissue Utilization before
enrolment in the study.
Samples
Archived formalin-fixed, paraffin-embedded tissue blocks were
stored and transported at room temperature. One tumor block
representing the deepest invasive margin was selected from each
tumor by microscopy performed by first a trainee and afterwards an
experienced pathologist.
Immunohistochemistry
Serial 4-μm sections were cut from the selected tumor blocks and
mounted on FLEX IHC Microscope Slides (K8020, DAKO,
Glostrup, Denmark). The pretreatment processes were performed
using PT Link (DAKO). Heat-induced epitope retrieval was achieved
with Envision Target Retrieval Solution (DAKO) at pH 9 and 97°C
for 20 minutes.
Staining was performed using a DAKO Autostainer Link 48
(DAKO). Endogenous peroxidase activity was blocked by Envision
FLEX Peroxidase-Blocking Reagent (DAKO). The primary antibod-
ies were mouse monoclonal anti-CD3 (code M7254, DAKO) diluted
1:600 and anti-CD8 (code M7103, DAKO) diluted 1:300. For
mismatch repair, we used monoclonal mouse antibody against MLH1
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code NCL-L-MLH1), MSH2 (Novocastra, Leica, clone 25D12,
dilution 1:100, product code NCL-L-MSH2), MSH6 (BD Trans-
duction Laboratories, clone 44/MSH6, dilution 1:200, material
number 610919), and PMS2 (BD Pharmingen, clone A16-4,
dilution 1:500, material number 556415).
The primary antibodies were diluted with Envision Flex antibody
diluent (code S2022 DAKO) and incubated for 30 minutes at room
temperature. For amplification, Envision Flex+ Mouse(Linker)
(DAKO) was used for 20 minutes. Bound antibodies were detected
using Envision FLEX/HRP (DAKO) and visualized by Envision
FLEX DAB (DAKO) and chromogene diluted in Envision Flex
Substrate Buffer (DAKO). To enhance the immunohistochemical
stains, the sections were incubated in 0.5% CuSO4 in TBS buffer
pH 7.6 for 10 minutes. Meyer's hematoxylin (Merck, Damstadt,
Germany) was used as counterstain, and finally, the histological slides
were cover-slipped with Tissue-Tek PERTEX (Histolab Products AB,
Göteborg, Sweden).
Quantification of TILs
Sections were scanned at 40× magnification using a NanoZoomer
XR scanner (Hamamatsu, Japan). The image format was NanoZoo-Figure 1. Photomicrographs of CD3 and CD8 immunohistochemistry
the bottom show low densities.mer Digital Pathology Image (*.ndpi) with a resolution of 226 nm/
pixel (112,389 dots per inch, i.e., 4.4 × 4.4 pixels/μm corresponding
to a final magnification of ×1.558). The quantification of TILs was
performed by digital image analysis using Visiopharm Integrator
System software (VIS; Visiopharm A/S, Hoersholm, Denmark)
(Figure 1). Regions of interest were manually delineated by the
observer in the software as an invasive area outlined as the outermost
front of the adenocarcinoma, including the deepest invasive front of
the tumor, areas with tumor budding and/or irregular tumor islands.
TILs were quantified as immune densities (cells/mm2) within both
cancer epithelium (intratumoral) and tumor-associated stroma
(peritumoral) as previously described [18]. In brief, we used an
app-based image analysis algorithm developed specifically for
counting of CD3+ and CD8+ lymphocytes. Artifacts, including
tissue folds and clefts, mucin, fatty tissue, and necrosis, were
automatically excluded to avoid contributions from regions of no
interest.
Statistics
OS was defined as the time between date of primary surgery and
date of death from any cause or the date of last follow-up. RFS was
defined as the time from date of primary surgery until date of death. The panels on the top show high cell densities, and the panels on
Table 1. Patient Characteristics and Association to CD3+ and CD8+ TILs
Number
(n = 573) (%)
CD3+ TILs CD8+ TILs
High (%) Low (%) P Value High (%) Low (%) P Value
Age (years) at diagnosis
Median 73
Range 29-95
≥73 268 (47) 185 (48) 83 (45) .475 211 (48) 57 (42) .165
b73 305 (53) 202 (52) 103 (55) 225 (52) 80 (58)
Gender
Male 284 (50) 185 (48) 99 (53) .224 217 (50) 67 (49) .860
Female 289 (50) 202 (52) 87 (47) 219 (50) 70 (51)
T-stage
pT3 501 (87) 342 (88) 159 (85) .329 383 (88) 118 (86) .598
pT4 72 (13) 45 (12) 27 (15) 53 (12) 19 (14)
Histology (WHO)
Adenocarcinoma NOS 516 (89) 353 (91) 163 (88) .076 393 (90) 123 (90) .687
Mucinous adenocarcinoma 55 (10) 34 (9) 21 (11) 42 (10) 13 (9)
Signet-ring cell carcinoma 2 (1) 0 2 (1) 1 (0.2) 1 (1)
Malignancy grade
Medium + low 451 (79) 298 (77) 153 (82) .150 334 (77) 117 (85) .028
High* 122 (21) 89 (23) 33 (18) 102 (23) 20 (15)
Localization
Right 273 (48) 195 (50) 78 (42) .058 219 (50) 54 (39) .027
Left 300 (52) 192 (50) 108 (58) 217 (50) 83 (60)
Tumor perforation
Yes 17 (3) 9 (2) 8 (4) .192 12 (3) 5 (4) .629





b12 nodes 352 218 (56) 134 (72) b.001 256 (59) 96 (70) .017
≥12 nodes 221 169 (44) 52 (28) 180 (41) 41 (30)
Perineural invasion
Yes 26 (5) 13 (5) 13 (10) .068 13 (5) 13 (13) .003
No 360 (63) 243 (95) 117 (90) 275 (95) 85 (87)
Not assessed 187 (32)
Vascular invasion
Yes 43 (7) 27 (9) 16 (11) .538 33 (10) 10 (9) .823
No 387 (68) 261 (91) 126 (89) 291 (90) 96 (91)
Not assessed 143 (25)
Mismatch repair status
MSS 400 (70) 243 (63) 157 (84) b.001 279 (64) 121 (88) b.001
MSI 173 (30) 144 (37) 29 (16) 157 (36) 16 (12)
Abbreviations: MSI, microsatellite instability; MSS, microsatellite stable; NOS, not otherwise specified.
P values are obtained using chi2 test.
* Including mucinous adenocarcinomas and signet-ring cell carcinomas.
982 Tumor-Infiltrating Lymphocytes in Stage II Colon Cancer Eriksen et al. Translational Oncology Vol. 11, No. xx, 2018from any cause or the date of first locoregional or distant recurrence.
Patients diagnosed with another cancer were censored at the date of
diagnosis. The Kaplan-Meier method was used to present survival
curves, and the log-rank test was used to test for significant differences
in survival time among the groups. We used the multiple Cox
regression model with a hazard ratio (HR) of 1.0 as reference and a
95% confidence interval (CI). A cutoff significance level of 0.10 was
prespecified for a parameter to be included in the multiple Cox
regression model.
The continuous TILs data were categorized into high and low
using cutoffs at 350 cells /mm2 for CD3+ and at 200 cells/mm2 for
CD8+ corresponding to the lower tertiles in both cases. Analyses of
associations between clinicopathological variables were carried out
using the chi-square test. All statistical analyses were performed using
the STATA software version 14.0 (StataCorp, College Station, TX),and all statistical tests were two-sided with P values less than .05
considered significant.Results
Patient Characteristics
Patient characteristics are summarized in Table 1. In the follow-up
period of 7 years, 266 (46.4%) patients died; 110 (19.2%) recurred,
and 78 (13.6%) patients were diagnosed with another cancer. The
median age at time of surgery was 73 years (range 29-95), and the
mean follow-up time was 6.9 years (range 3-84 months).
Tumor-Infiltrating Lymphocytes
The mean density of TILs was 607 (SD ± 441) cells/mm2 for
CD3+ and 470 (SD ± 394) cells/mm2 for CD8+. After
Figure 2. Kaplan-Meier survival curves for overall survival and recurrence-free survival.(A-B) CD3+ TILs and (C-D) CD8+ TILs in the total
patient population (n = 573).Invasive refers to the area of the outermost front of the adenocarcinoma, including the deepest invasive front
of the tumor, areas with tumor budding, and/or irregular tumor islands.
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as low-CD3+ and 387 (67.5%) CCs were classified as high-CD3+.
Regarding CD8, 185 (32.3%) and 338 (67.7%) CCs were classified
as low-CD8+ and high-CD8+, respectively. A total of 124 tumors
were classified as low TILs for both CD3+ and CD8+, while 374 CCs
were classified as high TILs for both CD3+ and CD8+. The
remaining 75 tumors were classified as combined high and low.
Low occurrence of CD3+ and CD8+ TILs was related to left-sided
CC (P = .058 and .027), low number of retrieved lymph nodes
(P b .001 and .017), and microsatellite stability (MSS) (P b .001).
Furthermore, low CD8+ TILs were associated with perineural
invasion (P = .003) and medium/low malignancy grade (P = .028).
Survival Analyses
The 5-year RFS rate for the population with low CD3+ TILs was
61.7% versus 72.7% in the group of patients with high CD3+ TILs,
and OS was 68.5% versus 77.4%. Similarly, the 5-year RFS rate for
the population with low CD8+ TILs was 59.5% versus 72.2% in the
group of patients with high CD8+ TILs, and OS was 65.6% versus
77.3%. Significant differences were observed for both RFS and OS
(Figure 2).
Results from the corresponding simple and multiple Cox regression
analyses are shown in Tables 2 and 3. Age ≥ 73, T4 tumor, and
perforation were significantly related to an adverse outcome regarding
OS. In addition, localization and MSI status were nearly significantly
related to RFS. In the simple analysis, low CD3+ and CD8+ TILs
were related to adverse outcome of both OS and RFS. In the multiple
analyses, low CD3+ and CD8+ TILs were associated with reduced
RFS, HR = 1.386 (1.039-1.850), P = .026 and HR = 1.394 (1.029-1.890), P = .032, respectively, and reduced OS, HR = 1.532 (1.142-
2.054), P = .004 and HR = 1.591 (1.169-2.166), P = .003, respective-
ly, independent of age, T-stage, localization, perforation, andMSI status.
Combining MSI status and TILs revealed a better prognosis for MSS
tumors with high TILs thanMSI tumors with lowTILs (Figure 3). There
was no difference in survival between patients withMSI andMSS tumors
in the subgroups of patients with low CD3+ (N = 186) or CD8+ (N =
137) TILs, P = .821 and P = .907, respectively. The subgroup of
patients with MSI tumors (N = 173) may experience decreased survival
in case of low CD3+ or CD8+ TILs compared to MSI tumors with high
CD3+ or CD8+ TILs. However, the difference did not reach statistical
significance (P = .0763 and P = .1060, respectively).
Discussion
We investigated the prognostic value of CD3+ and CD8+ TILs in the
invasive front of adenocarcinomas in an unbiased, nationwide,
population-based cohort of stage II CC patients treated exclusively
with surgery. We demonstrated an independent prognostic impact on
both OS and RFS with similar prognostic power afforded by CD3+
and CD8+ TILs.
Previous studies reporting data on stage II CRC and CD3+ TILs
have documented a prognostic value [12,13]; however, these studies
only included a subgroup of patients with stage II CC. Furthermore,
CD3+ TILs were evaluated as area fractions [12] or semiquantitatively
[13], while we evaluated TILs as density estimates using automatic
digital image analysis. Other studies using image analysis report
conflicting results. Nosho et al. [19] did not find densities of either
CD3+ or CD8+ TILs to be associated with survival in their study of
CRC. They included all stages, and stage II disease only represented a
Table 2. Cox Regression Analysis, OS (n = 573)




HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Age
b73 1 b.001 1 b.001 1 b.001
≥73 2.405 (1.774-3.260) 2.650 (1.930-3.638) 2.639 (1.922-3.622)
Sex
Male 1 .448 - - - -
Female 0.897 (0.678-1.187)
T-category
T3 1 .007 1 .004 1 .003
T4 1.662 (1.148-2.407) 1.748 (1.193-2.561) 1.777 (1.213-2.602)
Malignancy grade
Medium/Low 1 0.292 - - - -
High* 1.193 (0.859-1.656)
Localization
Right 1 0.201 - - - -
Left 1.202 (0.907-1.593)
Tumor perforation
No 1 .033 1 .017 1 .021
Yes 2.072 (1.059-4.052) 2.311 (1.161-4.600) 2.254 (1.132-4.489)
Lymph nodes
b12 nodes 1 .295 - - - -
≥12 nodes 0.856 (0.640-1.145)
Perineural invasion
No 1 .153 - - - -
Yes 1.540 (0.851-2.786)
Vascular invasion
No 1 .409 - - - -
Yes 1.237 (0.747-2.047)
Mismatch repair status
MSS 1 .272 - - - -
MSI 0.839 (0.613-1.148)
CD3-invasive
High 1 .002 1 .004 - -
Low 1.560 (1.173-2.076) 1.532 (1.142-2.054)
CD8-invasive
High 1 .001 - - 1 .003
Low 1.660 (1.229-2.245) 1.591 (1.169-2.166)
Invasive refers to the area of the outermost front of the adenocarcinoma, including the deepest invasive front of the tumor, areas with tumor budding, and/or irregular tumor islands.
* Including mucinous adenocarcinomas and signet-ring cell carcinomas.
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quantified in the neoplastic epithelial cells, not in the tumor-
associated stroma. Consequently, the TILs count by Nosho et al.
might not reflect the real immune reaction against the tumor cells
occurring in the tumor microenvironment. Turksma et al. [8]
evaluated TILs in stage II and III CC using image analysis and
demonstrated a prognostic value of both CD3+ and CD8+ TILs. In
this study, the prognostic impact was related to stromal CD3+ and
tumor epithelial CD8+ T-cells. We did not distinguish between
stromal and epithelial localization of T-cells but quantified the two
groups of TILs together. In accordance with previous studies [16],
our impression is that the highest density of TILs is in the stromal
compartment. We found mean densities of CD3+ to be 607 cells/
mm2 in the invasive area, which are comparable with results from the
stromal compartment in the study by Lee et al. [16]. They evaluated
TILs separately in the intraepithelial and stromal compartments in
stage II CC and found a significant association between CD3+ TILsand OS as well as disease-free survival when combining measurements
from both compartments. However, their study only included 87
patients, and their results were not significant in the multivariate
analysis. We investigated a large population-based cohort, and our
result remained significant in the multivariate analysis independent of
age, T-stage, localization, perforation, and MSI status. Also, we
investigated TILs in the entire invasive area of whole tumor slides,
while Lee et al. used hotspot sampling [16].
The Immunoscore project [5] includes combinations of TILs. We
investigated the prognostic value of the combination of CD3+ and
CD8+ TILs, but this did not add any additional prognostic value
(data not shown).
We found MSI tumors to have a significantly higher occurrence of
TILs compared to MSS tumors, which is in agreement with previous
studies [8,20]. The marked intratumoral infiltration of inflammatory
cells in MSI tumors might be related to the genetic instability in this
group of tumors. The unreliable DNA repair in MSI tumors results in
Table 3. Cox Regression Analysis, RFS (n = 573)




HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Age
b73 1 b.001 1 b.001 1 b.001
≥73 1.854 (1.405-2.446) 1.999 (1.499-2.668) 2.006 (1.504-2.675)
Sex
Male 1 0.440 - - - -
Female 0.901 (0.692-1.174)
T-category
T3 1 .009 1 .012 1 .011
T4 1.612 (1.128-2.305) 1.602 (1.108-2.315) 1.611 (1.115-2.328)
Malignancy grade
Medium/Low 1 .820 - - - -
High* 1.038 (0.754-1.429)
Localization
Right 1 .094 1 .159 1 .187
Left 1.256 (0.962-1.639) 1.251 (0.916-1.709) 1.233 (0.903-1.685)
Tumor perforation
No 1 .010 1 .014 1 .016
Yes 2.301 (1.218-4.349) 2.257 (1.178-4.325) 2.230 (1.161-4.280)
Lymph nodes
b12 nodes 1 .453 - - - -
≥12 nodes 0.901 (0.685-1.184)
Perineural invasion
No 1 .112 - - - -
Yes 1.585 (0.898-2.799)
Vascular invasion
No 1 .708 - - - -
Yes 1.100 (0.667-1.816)
Mismatch repair status
MSS 1 .057 1 .455 1 .400
MSI 0.746 (0.552-1.009) 0.870 (0.603-1.255) 0.855 (0.594-1.231)
CD3-invasive
High 1 .001 1 .026 - -
Low 1.549 (1.183-2.030) 1.386 (1.039-1.850)
CD8-invasive
High 1 .001 - - 1 .032
Low 1.621 (1.219-2.156) 1.394 (1.029-1.890)
Invasive refers to the area of the outermost front of the adenocarcinoma, including the deepest invasive front of the tumor, areas with tumor budding, and/or irregular tumor islands.
* Including mucinous adenocarcinomas and signet-ring cell carcinomas.
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specific antigens) that may trigger the immune system, including
recruitment and activation of cytotoxic T-cells [21]. MSI status is
known to have a strong prognostic value, and stage II CRC patients
with MSI tumors are often found to have a more favorable prognosis
[22]. This may partly be explained by the benefit from T-cell
infiltration.
The activated cytotoxic T-cells are capable of killing the cancer
cells, either by production and release of cytotoxic proteins such as
perforin and granzymes or destruction via Fas/FasL interactions [23].
Consistent with previous studies [8,13,21], we may hypothesize
the subgroup of patients with MSI tumors and low presence of CD3+
or CD8+ TILs to have decreased survival compared to MSI tumors
with high presence of CD3+ or CD8+ TILs. Interestingly, we found
no difference in RFS between patients with MSI and MSS tumors in
the subgroup of patients with low TILs. Dahlin et al. found no
difference in cancer-specific survival between MSI and MSS patientswith a similar degree of CD3+ T-cell infiltration [13], but another
study of all stages of CRC [14] reported MSS tumors with high
infiltration of CD8+ TILs to have a better OS. In our study, the
subgroups of patients with MSI and low TILs were small. This was
expected, but particular attention should be paid to this group of
patients since TILs may be an important prognostic marker in
combination with MSI status.
Some MSS tumors display a marked inflammatory reaction with
high presence of TILs.
Giannakis et al. [24] performed whole exome sequencing of 619
CRC and showed significant association between high neoantigen
load and high degree of TILs in analysis restricted to MSS tumors.
Thus, also within MSS tumors, the neoantigen load is a determinant
for the immune cell infiltration. On the other hand, some MSI
tumors display low TILs. This might be related to low neoantigen
load; however, the mutational burden in this group of patients
remains to be investigated.
Figure 3. Kaplan-Meier survival curves for recurrence-free survival for different combinations of TILs and MSI status (N = 573).(A) High
CD3+ TILs versus low CD3+ TILs and (B) high CD8+ TILs versus low CD8+ TILs.Invasive refers to the area of the outermost front of the
adenocarcinoma, including the deepest invasive front of the tumor, areas with tumor budding, and/or irregular tumor islands.
986 Tumor-Infiltrating Lymphocytes in Stage II Colon Cancer Eriksen et al. Translational Oncology Vol. 11, No. xx, 2018The present study is limited by the retrospective design, as we had
no influence on the preanalytical phase of the IHC. Moreover, data
on recurrence and death were obtained from registers, and the
individual patient records have not been evaluated. Especially the
cause of death may be questionable, and therefore, we did not use a
cancer-specific endpoint.
The tumor microenvironment is complex, and the presence of
specific T-cell subsets should be interpreted with caution, as other
factors in the tumor microenvironment may influence the compo-
sition of TILs and thus tumor progression. However, CD3+ and
CD8+ TILs represent variables investigated in various settings, and
the study group behind the Immunoscore recommends analysis of
these two particular T-cell groups [11].
Conclusion
In conclusion, a low level of CD3+ or CD8+ TILs in the invasive
tumor front is related to an inferior prognosis in patients with stage II
CC. We recommend either low CD3+ or CD8+ TILs at the invasive
front to be considered as an additional high-risk parameter. Particular
attention should be paid to future studies of patients with MSI
tumors and low CD8+ TILs, as the prognosis of this subgroup may be
unexpectedly poor.
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